Clinical Trial Update: Second-line FOLFIRI + Panitumumab in Subjects With Wild Type RAS Metastatic Colorectal [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating second-line FOLFIRI plus panitumumab in patients with wild-type RAS metastatic colorectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• FOLFIRI (irinotecan, leucovorin, 5-fluorouracil)
• Panitumumab (panitumumab)

Snippet

Sponsor: Grupo Espanol Multidisciplinario del Cancer Digestivo | Conditions: Colorectal Cancer Metastatic | Phase 2 | Status: UNKNOWN